(Q35629061)

9 August 2017

1 reference

title

First-line treatment strategies to improve survival in patients with advanced colorectal cancer (English)

1 reference

9 August 2017

1 reference

1 reference

Sharlene Gill

1

1 reference

PubMed ID

14723557

9 August 2017

Richard M Goldberg

series ordinal

2

1 reference

9 August 2017

1 January 2004

1 reference

9 August 2017

1 reference

9 August 2017

64

1 reference

9 August 2017

1

1 reference

9 August 2017

27-44

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200464010-00003

9 August 2017

0 references

cites work

A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil

1 reference

12 December 2020

Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study

1 reference

12 December 2020

Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules

1 reference

12 December 2020

Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer

1 reference

12 December 2020

A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer

1 reference

12 December 2020

Surgical therapy of hepatic colorectal metastasis

1 reference

12 December 2020

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

1 reference

12 December 2020

Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.

1 reference

12 December 2020

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma

1 reference

12 December 2020

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum

1 reference

12 December 2020

Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study

1 reference

12 December 2020

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

12 December 2020

Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures

1 reference

12 December 2020

Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients

1 reference

12 December 2020

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial

1 reference

12 December 2020

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

12 December 2020

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study

1 reference

12 December 2020

Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil

1 reference

12 December 2020

Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group

1 reference

12 December 2020

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

1 reference

12 December 2020

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

12 December 2020

Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer

1 reference

12 December 2020

Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

1 reference

12 December 2020

The natural history of primary and secondary malignant tumors of the liver I.The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy

1 reference

12 December 2020

Safety of raltitrexed

1 reference

12 December 2020

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

12 December 2020

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin

1 reference

12 December 2020

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

12 December 2020

Cancer statistics, 2002

1 reference

12 December 2020

Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1

1 reference

12 December 2020

Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2'-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism

1 reference

12 December 2020

Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer

1 reference

12 December 2020

Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer

1 reference

12 December 2020

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

12 December 2020

Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy

1 reference

12 December 2020

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study

1 reference

12 December 2020

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

12 December 2020

Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program

1 reference

12 December 2020

Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer.

1 reference

12 December 2020

Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study

1 reference

12 December 2020

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

1 reference

12 December 2020

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

12 December 2020

Surgical treatment of hepatic and pulmonary metastases from colon cancer

1 reference

12 December 2020

Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastroint

1 reference

12 December 2020

Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study

1 reference

12 December 2020

Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats

1 reference

12 December 2020

Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

1 reference

12 December 2020

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

12 December 2020

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

12 December 2020

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

1 reference

12 December 2020

Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer

1 reference

12 December 2020

Microsatellite instability in cancer of the proximal colon

1 reference

12 December 2020

Mature results from three large controlled studies with raltitrexed ('Tomudex').

1 reference

12 December 2020

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

12 December 2020

A genetic model for colorectal tumorigenesis

1 reference

12 December 2020

1 reference

12 December 2020

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

1 reference

12 December 2020

Continuous low-dose infusion of fluorouracil: is the benefit worth the cost?

1 reference

12 December 2020

EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer

1 reference

12 December 2020

Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors

1 reference

12 December 2020

Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer

1 reference

12 December 2020

Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.

1 reference

12 December 2020

Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.

1 reference

12 December 2020

A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma

1 reference

12 December 2020

Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation

1 reference

12 December 2020

Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer

1 reference

12 December 2020

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

12 December 2020

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

12 December 2020

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity

1 reference

12 December 2020

A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP)

1 reference

12 December 2020

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

12 December 2020

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

12 December 2020

Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity

1 reference

12 December 2020

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

1 reference

12 December 2020

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

1 reference

12 December 2020

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

1 reference

12 December 2020

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

12 December 2020

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer

1 reference

12 December 2020

Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer

1 reference

12 December 2020

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

12 December 2020

Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer

1 reference

12 December 2020

Global cancer statistics in the year 2000.

1 reference

12 December 2020

Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

12 December 2020

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

1 reference

12 December 2020

Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer

1 reference

12 December 2020

Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors

1 reference

12 December 2020

Oxaliplatin: mechanism of action and antineoplastic activity

1 reference

12 December 2020

Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

12 December 2020

Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.

1 reference

12 December 2020

Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery

1 reference

12 December 2020

Emerging pathways in colorectal-cancer development

1 reference

12 December 2020

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group

1 reference

12 December 2020

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer

1 reference

12 December 2020

Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer

1 reference

12 December 2020

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

12 December 2020

Pharmacokinetics of the fluoropyrimidines: implications for their clinical use

1 reference

12 December 2020

Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer

1 reference

12 December 2020

Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer

1 reference

12 December 2020

Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells

1 reference

12 December 2020

Drug-company decision to end cancer trial

1 reference

12 December 2020

Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data

1 reference

12 December 2020

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

12 December 2020

CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR

1 reference

12 December 2020

10.2165/00003495-200464010-00003

Identifiers

DOI

1 reference

PubMed ID

14723557

Dimensions Publication ID

9 August 2017

0 references

1 reference

PubMed ID

14723557